Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Rhea-AI Summary

Arvinas (Nasdaq: ARVN) will present Phase 1 human data for ARV-102, an oral PROTAC degrader targeting LRRK2, at AD/PD 2026 in Copenhagen. The presentation on March 18, 2026 at 3:30 PM CET covers safety, pharmacokinetics, and pharmacodynamics in participants with Parkinson’s disease.

Key Figures

Year-end cash: $685.4M Cash runway: into 2H 2028 PDUFA date: June 5, 2026 +5 more

8 metrics

Year-end cash $685.4M Cash, cash equivalents and marketable securities at Dec 31, 2025

Cash runway into 2H 2028 Guided runway from Feb 24, 2026 earnings update

PDUFA date June 5, 2026 FDA review timeline for vepdegestrant NDA

VERITAC-2 enrollment 624 patients Phase 3 vepdegestrant trial population

ESR1-mutated subset 270 patients Patients with ESR1 mutations in VERITAC-2

ARV-102 single dose up to 200 mg Well-tolerated Phase 1 single doses reported Oct 2025

ARV-102 multiple dose 80 mg daily Well-tolerated 14-day dosing in Phase 1 healthy volunteers

Pre-news price move +3.44% ARVN one-day change to <b>$13.83</b> before AD/PD 2026 data

Market Reality Check

Price: $13.83 Vol: Volume 734,974 is below t...

normal vol

$13.83 Last Close

Volume Volume 734,974 is below the 20-day average of 883,321, suggesting no outsized trading interest ahead of the data presentation. normal

Technical Shares at $13.83 are trading above the 200-day MA of $9.81, indicating a recovery from prior lows before this clinical update.

Peers on Argus

ARVN is up 3.44% while close peers show mixed moves (e.g., OLMA -3.84%, NRIX +1....

1 Up

ARVN is up 3.44% while close peers show mixed moves (e.g., OLMA -3.84%, NRIX +1.99%, XNCR +0.25%), and only one momentum peer (ANAB +5.87%) screens without news, pointing to a stock-specific reaction to its clinical catalyst.

Previous Clinical trial Reports

5 past events · Latest: Nov 24 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 24	Conference data updates	Positive	+2.2%	Multiple vepdegestrant clinical abstracts accepted for SABCS presentation with detailed analyses.
Oct 24	Preclinical data release	Positive	+4.8%	Preclinical ARV-806 KRAS G12D data showed robust degradation and tumor volume reductions.
Oct 20	Phase 3 PRO data	Positive	+2.1%	VERITAC-2 patient-reported outcomes supported vepdegestrant clinical benefit in ESR1m breast cancer.
Oct 05	Phase 1 ARV-102 data	Positive	+0.1%	Late-breaking ARV-102 Phase 1 data showed tolerability, brain penetration and strong LRRK2 reduction.
Aug 08	NDA acceptance	Positive	+4.7%	FDA accepted vepdegestrant NDA for ESR1m ER+/HER2- breast cancer with a defined PDUFA date.

Pattern Detected

Clinical and regulatory PROTAC updates have generally produced modest positive one-day moves, with several same-tag events showing gains in the low- to mid-single digits.

Recent Company History

Over the past year, Arvinas has repeatedly highlighted progress across its PROTAC pipeline. Key milestones include FDA acceptance of the vepdegestrant NDA with a June 5, 2026 PDUFA date, multiple VERITAC-2 data readouts, and new preclinical ARV-806 results. ARV-102 already showed encouraging Phase 1 data in October 2025. Today’s planned Phase 1 data presentation for ARV-102 at AD/PD 2026 continues this sequence of incremental, data-driven updates.

Historical Comparison

+2.8% avg move · Past clinical-trial headlines for Arvinas produced an average one-day move of 2.77%. A similar-sized...

clinical trial

+2.8%

Average Historical Move clinical trial

Past clinical-trial headlines for Arvinas produced an average one-day move of 2.77%. A similar-sized reaction to this ARV-102 Phase 1 presentation would be consistent with that pattern.

Clinical updates show a maturing PROTAC portfolio, from ARV-102 Phase 1 data through robust ARV-806 preclinical results to vepdegestrant’s NDA acceptance and VERITAC-2 Phase 3 outcomes.

Market Pulse Summary

This announcement highlights planned Phase 1 safety, pharmacokinetic, and pharmacodynamic data for A...

Analysis

This announcement highlights planned Phase 1 safety, pharmacokinetic, and pharmacodynamic data for ARV-102, a brain-penetrant PROTAC LRRK2 degrader for Parkinson’s disease, to be presented at AD/PD 2026 on March 18, 2026. In context of prior positive ARV-102 data and broader PROTAC milestones, investors may track consistency of safety signals, evidence of target engagement in humans, and how these readouts position the program for subsequent development stages.

Key Terms

pharmacokinetic, pharmacodynamic, proteolysis targeting chimera, protac, +4 more

8 terms

pharmacokinetic medical

"Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1..."

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

pharmacodynamic medical

"Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1..."

Pharmacodynamic describes how a drug acts on the body — the biological effects it produces, how strong those effects are, and how long they last. For investors, pharmacodynamic data show whether a treatment actually works and at what dose, shaping expectations about a drug’s safety, effectiveness, regulatory success and market potential; think of it like testing how well a key turns a lock and whether it reliably opens the door.

proteolysis targeting chimera medical

"ARV-102 is Arvinas’ investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC)..."

A proteolysis targeting chimera (often called a PROTAC) is a small molecule that links a disease-causing protein to the cell’s natural disposal machinery so the protein is broken down and removed. Think of it as a guided tag that sends a faulty part to the cell’s garbage truck. Investors care because this mechanism can enable entirely new types of drugs, offering potential high reward but also unique technical and regulatory risks.

protac medical

"ARV-102 is Arvinas’ investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC)..."

A PROTAC (proteolysis targeting chimera) is a small engineered molecule that tags a specific protein inside cells and brings it to the cell’s disposal machinery so the protein is destroyed rather than just blocked. Think of it as a targeted cleanup crew that removes a problematic part instead of temporarily turning it off. Investors care because PROTACs can tackle disease targets that traditional drugs cannot, creating potential for breakthrough therapies, larger markets, and binary clinical readouts that can sharply affect company value.

blood-brain barrier medical

"PROTAC degrader designed to cross the blood-brain barrier and target leucine-rich repeat..."

A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.

leucine-rich repeat kinase 2 medical

"target leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated..."

Leucine-rich repeat kinase 2 (LRRK2) is a protein made from a gene that acts like a tiny molecular switch inside brain cells, altering other proteins' behavior by adding chemical tags. It matters to investors because certain changes in LRRK2 are linked to Parkinson’s disease and other neurological disorders, making it a major target for drug development, diagnostics, and clinical trials; progress or setbacks around LRRK2 programs can strongly affect biotech valuations.

lrrk2 medical

"target leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated..."

LRRK2 is a human gene that produces a protein involved in how brain cells communicate and clear waste; specific changes in this gene can raise the risk of Parkinson’s disease. For investors, it matters because drugs or diagnostics that target LRRK2 are a clear pathway for new treatments — like repairing a faulty part in a machine — so clinical results, approvals, or setbacks around LRRK2 programs can meaningfully affect a biotech or pharmaceutical company’s value.

phase 1 clinical trial medical

"data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease..."

A phase 1 clinical trial is the first stage of testing a new drug or treatment in people, typically involving a small group to assess safety, how the body handles the treatment, and appropriate dosing. For investors, phase 1 results are an early risk check — like a test drive that can reveal fatal flaws or promising signals — and they often cause big changes in a drug’s perceived value and the company’s prospects.

AI-generated analysis. Not financial advice.

– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease –

NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease (PD) will be presented at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026), March 17-21, 2026, in Copenhagen, Denmark. ARV-102 is Arvinas’ investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in PD and progressive supranuclear palsy (PSP).

Presentation details are as follows:

Presentation Title: Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ARV-102, a PROTAC LRRK2 Degrader, in Participants with Parkinson’s Disease

Session Title: Modulating Neuroinflammation, Α-Synuclein, LRRK2, and Dopaminergic Repair: Early Human Data

Session Type: Symposium

Session Location: Hall 180-181 

Date: March 18, 2026

Lecture Time: 3:30-3:45 PM CET

The full abstract can be accessed via the AD/PD™ 2026 interactive program.

About ARV-102

ARV-102 is an investigational, orally bioavailable PROTAC designed to cross the blood-brain barrier and specifically target and degrade leucine-rich repeat kinase (LRRK2), a large, multidomain scaffolding kinase with GTPase activity. Increased activity and overexpression of LRRK2 have been implicated in the pathogenesis of neurological diseases, including Parkinson’s disease and progressive supranuclear palsy (PSP). ARV-102 is currently being evaluated in a Phase 1 clinical trial in patients with Parkinson’s disease and Arvinas plans to initiate a Phase 1b clinical trial with ARV-102 in patients with PSP, pending regulatory feedback, in the first half of 2026.

About Arvinas

Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the potential of ARV-102, including its degradation of leucine-rich repeat kinase 2, and potential future benefit to patients; and Arvinas’ plans with respect to ARV-102, including, pending regulatory feedback, the initiation of a Phase 1b clinical trial of ARV-102 in patients with progressive supranuclear palsy, and the timing thereof. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, development plans, future operations, prospects, plans and objectives of management and the statements identified in the prior paragraph, are forward-looking statements. The words “ability,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “target,” “goal,” “potential,” “whether,” “will,” “would,” “could,” “reliance,” “should,” “look forward,” “seek,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-102, on its current timelines or at all; risks related to clinical trial results and the interpretation thereof, including with respect to ARV-102; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalents will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent other reports filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
jeff.boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
kirsten.owens@arvinas.com

FAQ

When will Arvinas (ARVN) present Phase 1 ARV-102 data at AD/PD 2026?

Arvinas will present on March 18, 2026 at 3:30-3:45 PM CET in Hall 180-181. According to Arvinas, the oral lecture covers multiple-dose safety, pharmacokinetics, and pharmacodynamics from the Phase 1 trial in participants with Parkinson’s disease.

What type of data for ARV-102 will Arvinas (ARVN) present at AD/PD 2026?

The presentation will report safety, pharmacokinetic, and pharmacodynamic data from a Phase 1 multiple-dose study. According to Arvinas, the data reflect early human results in participants with Parkinson’s disease assessing tolerability and target engagement of ARV-102.

What is ARV-102 and how does it relate to Parkinson’s disease for ARVN investors?

ARV-102 is an oral PROTAC degrader designed to cross the blood-brain barrier and target LRRK2. According to Arvinas, LRRK2 is implicated in Parkinson’s disease and related disorders, and ARV-102 aims to reduce pathogenic LRRK2 via targeted protein degradation.

Where can investors access the ARV-102 abstract from Arvinas (ARVN) presented at AD/PD 2026?

The full abstract is available through the AD/PD 2026 interactive program linked by the conference. According to Arvinas, attendees and interested investors can view the abstract via the official AD/PD 2026 program portal for session details.

Which session will include Arvinas (ARVN) ARV-102 early human data at AD/PD 2026?

The data appear in the symposium 'Modulating Neuroinflammation, Α-Synuclein, LRRK2, and Dopaminergic Repair: Early Human Data.' According to Arvinas, the lecture will focus on early clinical evidence of target modulation and safety in Parkinson’s disease participants.

How long is the ARV-102 presentation by Arvinas (ARVN) at AD/PD 2026 and what format is it?

The presentation is a 15-minute oral lecture scheduled for March 18, 2026 from 3:30 to 3:45 PM CET. According to Arvinas, the session format is a symposium oral talk summarizing Phase 1 multiple-dose safety and PK/PD findings.